• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Search Orphan Drug Designations and Approvals

  • Print
  • Share
  • E-mail
-
 
Generic Name:  Recombinant Bispecific antibody targeting CD123 and CD3
Trade Name:  N/A
Date Designated:  11/26/2019
Orphan Designation:  Treatment of acute myelogenous leukemia
Orphan Designation Status:  Designated
FDA Orphan Approval Status: Not FDA Approved for Orphan Indication
Marketing Approval Date:  N/A
Approved Labeled Indication:  
Exclusivity End Date:    N/A
Aptevo Research and Development
2401 Fourth Avenue
Suite 1050
Seattle, Washington 98121
USA

The sponsor address listed is the last reported by the sponsor to OOPD.
-
-